Anemia in Chronic Kidney Disease

Chronic Kidney Disease, Dialysis, & Transplantation

Volumn , Issue , 2005, Pages 122-135

  Fishbane, Steven ^a,b   Masani, Naveed ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052166505     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0158-4.50011-2     Document Type: Chapter

References (209)

1. Kazmi WH, Kausz AT, Khan S, et al. Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 2001, 38(4):803-812.
2. Eschbach JW, Adamson JW Anemia of end-stage renal disease ESRD. Kidney Int 1985, 28:1-5.
3. Xue JL, St Peter WL, Ebben JP, et al. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002, 40(6):1153-1161.
4. Obrador GT, Ruthazer R, Arora P, et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999, 10(8):1793-1800.
5. Loge JP, Lange RD, Moore CV Characterization of the anemia associated with chronic renal insufficiency. Am J Med 1958, 24:4-18.
6. Radtke HW, Rege AB, Lamarche B, et al. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 1981, 67:1623-1629.
7. Massry SG Is parathyroid hormone an uremic toxin?. Nephron 1977, 19:125-130.
8. Fisher JW, Hatch FE, Roh BL, et al. Erythropoietin inhibitor in kidney extracts and plasma from anemic uremic human subjects. Blood 1968, 31(4):440-452.
9. Erslev AJ, Besarab A The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 1995, 126:283-286.
10. Eschbach JW The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989, 35:134-148.
11. Eschbach JW, Detter JC, Adamson JW Physiologic studies in normal and uremic sheep. II. Changes in erythropoiesis and oxygen transport. Kidney Int 1980, 18(6):732-745.
12. Noguchi CT, Bae KS, Chin K, et al. Cloning of the human erythropoietin receptor gene. Blood 1991, 78:2548-2556.
13. Ge RL, Witkowski S, Zhang Y, et al. Determinants of erythropoietin release in response to short-term hypobaric hypoxia. J Appl Physiol 2002, 92(6):2361-2367.
14. Levine BD Intermittent hypoxic training: Fact and fancy. High Alt Med Biol 2002, 3:177-193.
15. Ema M, Taya S, Yokotani N, et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997, 94:4273-4278.
16. Fisher JW Erythropoietin: Physiology and pharmacology update. Exp Biol Med (Maywood). 2003, 228(1):1-14.
17. 2 sensing. Science 2001, 292:464-468.
18. Epstein ACR, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by propyl hydroxylation. Cell 2001, 107:43-54.
19. Gopfert T, Gess B, Eckardt KV, Kurtz A Hypoxia signalling in the control of erythropoietin gene expression in rat hepatocytes. J Cell Physiol 1996, 168(2):354-361.
20. Graber SE, Krantz SB Erythropoietin and the control of red cell production. Ann Rev Med 1978, 29:51-66.
21. Fisher JW Erythropoietin: Physiology and pharmacology update. Exp Biol Med 2003, 228(1):1-14.
22. Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397-409.
23. Carroll MP, Spivak JL, McMahon M, et al. Erythropoietin induces Raf-1 activation is required for erythropoietin-mediated proliferation. J Biol Chem 1991, 266:14964-14969.
24. Fujitani Y, Hibi M, Fukada Y, et al. An alternative pathway for STAT activation that is mediated by the direct interaction between Jak and Stat. Oncogene 1997, 14:751-761.
25. Nagata Y, Kiefer F, Watanabe T, Todokoro K Activation of hematopoietic progenitor kinase-1 by erythropoietin. Blood 1999, 93:3347-3354.
26. Adamson JW The relationship of erythropoietin and iron metabolism to red blood cell production in humans. Semin Oncol 1994, 21(2 Suppl 3):9-15.
27. Ma JZ, Ebben J, Xia H, Collins AJ Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999, 10(3):610-619.
28. Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996, 28(1):53-61.
29. Lowrie EG, Lew N Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990, 15(5):458-482.
30. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001, 38(4):955-962.
31. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339(9):584-590.
32. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36% to 39%. J Am Soc Nephrol 2001, 12(11):2465-2473.
33. Churchill DN, Taylor DW, Cook RJ, et al. Canadian hemodialysis morbidity study. Am J Kidney Dis 1992, 19(3):214-234.
34. Larsh SE Anemia and symptoms. Ann Intern Med 1967, 66(1):234-235.
35. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 1990, 300:573-578. Canadian Erythropoietin Study Group.
36. Laupacis A, Wong C, Churchill D The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Control Clin Trial 1991, 12(suppl 4):68-179.
37. McMahon LP, Dawborn JK Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992, 12:162-169.
38. Moreno F, Aracil FJ, Perez R, Valderrabano F Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996, 27:548-556.
39. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 2000, 11:335-342.
40. McMahon LP, Mason K, Skinner SL, et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000, 15:1425-1430.
41. Painter P, Moore G, Carlson L, et al. Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. Am J Kidney Dis 2002, 39(2):257-265.
42. Ross SD, Fahrbach K, Frame D, et al. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clin Ther 2003, 25(6):1786-1805.
43. Wolcott DL, Marsh JT, La Rue A, et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989, 14(6):478-485.
44. Silverberg DS, Wexler D, Blum M, et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001, 21(suppl 3):S236-S240.
45. Marsh JT, Brown WS, Wolcott D, et al. RHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991, 39(1):155-163.
46. Temple RM, Deary IJ, Winney RJ Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis. Nephrol Dial Transplant 1995, 10(9):1733-1738.
47. Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999, 33(6):1122-1130.
48. Crowell JW, Frod RG, Lews VM Oxygen transport in hemorrhagic shock as a function of the hematocrit ratio. Am J Physiol 1959, 196(5):1033-1038.
49. Jan KM, Chien S Effect of hematocrit variations on coronary hemodynamics and oxygen utilization. Am J Physiol 1977, 233(1):106-113.
50. Benz RL, Pressman MR, Hovick ET, Peterson DD A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999, 34(6):1089-1095.
51. Harnett JD, Kent GM, Barre PE, et al. Risk factors for the development of left ventricular hypertrophy in a prospective cohort of dialysis patients. J Am Soc Nephrol 1994, 4:1486-1490.
52. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996, 11:1277-1285.
53. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996, 27:347-354.
54. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999, 34(1):125-134.
55. Harnett JD, Kent GM, Foley RN, Parfrey PS Cardiac function and hematocrit level. Am J Kidney Dis 1995, 25(4 Suppl 1):S3-S7.
56. Frohlich E Left ventricular hypertrophy as a risk factor. Cardiol Clin 1986, 4:137-145.
57. Kannel WB, Abbott R A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: The Framingham Study. Am Heart J 1986, 111:391-397.
58. Silberberg JS, Barre PE, Prichard SS, Sniderman AD Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989, 36:286-290.
59. Devereaux PJ, Schunemann HJ, Ravindran N, et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: A systematic review and metaanalysis. JAMA 2002, 288(19):2449-2457.
60. Silberberg J, Racine N, Barre P, Sniderman AD Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990, 6:31-37.
61. Cannella G, La Canna G, Sandrini M, et al. Reversal of left hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uremic patients. Nephrol Dial Transplant 1991, 6:31-37.
62. Massimetti C, Pontillo D, Feriozzi S, et al. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif 1998, 16(6):317-324.
63. Portoles J, Torralbo A, Martin P, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997, 29(4):541-548.
64. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000, 35(2):250-256.
65. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000, 58(3):1325-1335.
66. Conlon PJ, Kovalik E, Schumm D, et al. Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. Ren Fail 2000, 22(2):205-211.
67. Wizemann V, Kaufmann J, Kramer W Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992, 62(2):161-165.
68. Hase H, Imamura Y, Nakamura R, et al. Effects of rHuEPO therapy on exercise capacity in hemodialysis patients with coronary artery disease. Jpn Circ J 1993, 57(2):131-137.
69. Williams DM, Zimmers TA, Pierce JH, et al. The expression and role of human erythropoietin receptor in erythroid and non-erythroid cells. Ann N Y Acad Sci 1994, 718:232-243.
70. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985, 313(6005):806-810.
71. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987, 316(2):73-78.
72. Akizawa T, Koshikawa S, Takaku F, et al. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multi-institutional study in Japan. Int J Artif Organs 1988, 11(5):343-350.
73. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci 1985, 82:7580-7584.
74. Egrie JC, Strickland TW, Lane J, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 1986, 72:213-224.
75. Nissenson A Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 2001, 38(6):1390-1397.
76. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin α in dialysis patients. J Am Soc Nephrol 1999, 10(11):2392-2395.
77. Barnett AL, Cremieux PY Dose conversion from epoetin& to darbepoetin& for patients with chronic kidney disease receiving hemodialysis. Pharmacotherapy 2003, 23(5):690-693.
78. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001, 60(2):741-747.
79. Nissenson A Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 2001, 38(6):1390-1397.
80. Nissenson A, Swan S, Lindberg JS, et al. Randomized, controlled trial of darbepoetin& for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002, 40(1):110-118.
81. Macdougall IC An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001, 16(suppl 3):14-21.
82. TM Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000. Am J Kidney Dis 2001, 37(suppl 1):S182-S238. National Kidney Foundation.
83. Ifudu O Care of patients undergoing hemodialysis. N Engl J Med 1998, 339:1054-1062.
84. Albitar S, Genin R, Fen-Chong M, et al. High dose enalapril impairs the response to erythropoietin in hemodialysis patients. Nephrol Dial Transplant 1998, 13:1206.
85. Odabas AR, Cetinkaya R, Selcuk Y, et al. The effect of high dose losartan on erythropoietin resistance in patients undergoing hemodialysis. Paminerva Medica 2003, 45:59-62.
86. Minetti L Erythropoietin treatment in renal anemia. How high should the target hematocrit be?. J Nephrol 1997, 10(3):117-119.
87. Tonelli M, Winkelmayer WC, Jindal KK, et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003, 64(1):295-304.
88. Strippoli GF, Manno C, Schena FP, Craig JC Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev 2003, (1). CD003967.
89. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs cooperative study group on erythropoietin in hemodialysis patients. N Engl J Med 1998, 339(9):578-583.
90. McClellan WM, Frankenfield DL, Wish JB, et al. End-Stage Renal Disease Core Indicators work group. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis 2001, 37(5):E36.
91. Paganini EP, Eschbach JW, Lazarus JM, et al. Intravenous versus subcutaneous dosing of epoetin& in hemodialysis patients. Am J Kidney Dis 1995, 26(2):331-340.
92. Nowicki M Erythropoietin and hypertension. J Hum Hypertens 1995, 9(2):81-88.
93. Luft FC Erythropoietin and arterial hypertension. Clin Nephrol 2000, 53(suppl 1):S61-S64.
94. Garcia DL, Anderson S, Rennke HG, Brenner BM Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A 1988, 85(16):6142-6146.
95. Bode-Boger SM, Boger RH, Kuhn M, et al. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996, 50:1255.
96. Vaziri ND Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999, 33(5):821-828.
97. Jones MA, Kingswood JC, Dallyn PE, et al. Changes in diurnal blood pressure variation and red cell and plasma volumes in patients with renal failure who develop erythropoietin-induced hypertension. Clin Nephrol 1995, 44(3):193-200.
98. Caravaca F, Pizarro JL, Arrobas M, et al. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 1994, 45(3):845-851.
99. Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003, 98(7):1514-1520.
100. Churchill DN, Muirhead N, Goldstein M, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 1994, 4(10):1809-1813.
101. Besarab A, Medina F, Musial E, et al. Recombinant human erythropoietin does not increase clotting in vascular accesses. ASAIO Trans 1990, 36(3):M749-M753.
102. De Marchi S, Cecchin E, Falleti E, et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 1997, 8:1147-1156.
103. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346(7):469-475.
104. Casadevall N Antibodies against rHuEPO: Native and recombinant. Nephrol Dial Transplant 2002, 17(suppl 5):42-47.
105. Macdougall IC An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001, 16(Suppl):14-21.
106. Eschbach JW, Adamson JW Guidelines for recombinant human erythropoietin therapy. Am J Kidney Dis 1989, 14(2 suppl 1):2-8.
107. Macdougall IC Meeting the challenges of a new millennium: Optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998, 13(Suppl 2):23-27.
108. Brittenham GM Disorders of iron metabolism: Iron deficiency and overload. Hematology Basic Principles and Practice 1995, Churchill Livingstone, New York. 2nd ed. R. Hoffman, E.J. Benz, S.J. Shattil (Eds.).
109. Bridges KR, Seligman PA Disorders of iron metabolism. Blood: Principles and Practice of Hematology 1995, 1433-1472. Lippincott, Philadelphia. R.I. Handin, S.E. Lux, T.P. Stossel (Eds.).
110. Van Wyck DB Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis 1989, 14(2 suppl 1):9-13.
111. Akmal M, Sawelson S, Karubian F, Gadallah M The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 1994, 42(3):198-202.
112. Fishbane S, Maesaka JK Iron management in end-stage renal disease. Am J Kidney Dis 1997, 29(3):319-333.
113. Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol 2002, 42(10):1171-1176.
114. Cook JD, Dassenko SA, Whittaker P Calcium supplementation: Effect on iron absorption. Am J Clin Nutr 1991, 53(1):106-111.
115. Skikne BS, Ahluwalia N, Fergusson B, et al. Effects of erythropoietin therapy on iron absorption in chronic renal failure. J Lab Clin Med 2000, 135(6):452-458.
116. Brugnara C, Colella GM, Cremins J, et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 1994, 123(5):660-667.
117. Rogers JT, Bridges KR, Durmowicz GP, et al. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 1990, 265(24):14572-14578.
118. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996, 7:2654-2657.
119. Kalantar-Zadeh K, Hoffken B, Wunsch H, et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995, 26:292-299.
120. Low CL, Bailie GR, Eisele G Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients. Ren Fail 1997, 19(6):781-788.
121. Rahmati MA, Craig RG, Homel P, et al. Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis 2002, 40(5):983-989.
122. Owen WF, Lowrie EG C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998, 54(2):627-636.
123. Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001, 60:2406-2411.
124. Macdougall IC What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rHuEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant 1998, 13:847-849.
125. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001, 16:1416-1423.
126. Olivieri O, de Franceschi L, de Gironcoli M, et al. Potassium loss and cellular dehydration of stored erythrocytes following incubation in autologous plasma: Role of the KCl cotransport system. Vox Sang 1993, 65:95-102.
127. Cullen P, Soffker J, Hopfl M, et al. Hypochromic red cells and reticulocyte haemoglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant 1999, 14:659-665.
128. Fishbane S, Galgano C, Langley RC, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997, 52:217-222.
129. Koepke JF, Koepke JA Reticulocytes. Review. Clin Lab Haematol 1986, 8(3):169-179.
130. Bhandari S, Norfolk D, Brownjohn A, Turney J Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. Am J Kidney Dis 1997, 30:814-821.
131. Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997, 30(6):912-922.
132. Hallberg L, Ryttinger L, Solvell L Side effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand 1966, 459(Suppl):3-10.
133. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996, 50:1694-1699.
134. Wingard RL, Parker RA, Ismail N, Hakim RM Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995, 25:433-439.
135. Markowitz GS, Kahn GA, Feingold RE, et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997, 48:34-40.
136. Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 1998, 79:299-305.
137. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990, 150:1881-1884.
138. Fishbane S, Frei GL, Maesaka J Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995, 26:41-46.
139. Sunder-Plassmann G, Horl WH Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995, 10:2070-2076.
140. Taylor JE, Peat N, Porter C, Morgan AG Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996, 11:1079-1083.
141. Senger JM, Weiss RJ Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J 1996, 23(3):319-323.
142. Fishbane S, Lynn RI The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 1995, 44:238-240.
143. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000, 11:530-538.
144. Ahsan N Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single center comparative study. J Am Soc Nephrol 1998, 9(4):664-668.
145. Working party for European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999, 14(Suppl 5):1-50. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure.
146. Ali M, Rigolosi R, Fayemi AO, et al. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1982, 1(8273):652-655.
147. Javier AM Weekly administration of high-dose sodium ferric gluconate is safe and effective in peritoneal dialysis patients. Nephrol Nurs J 2002, 29(2):183-186.
148. Jain AK, Bastani B Safety profile of a high dose ferric gluconate in patients with severe chronic renal insufficiency. J Nephrol 2002, 15(6):681-683.
149. Kumpf VJ, Holland EG Parenteral iron dextran therapy. DICP 1990, 24(2):162-166.
150. Geisser P, Baer M, Schaub E Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992, 42(12):1439-1452.
151. Faich G, Strobos J Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999, 33(3):464-470.
152. Fleming LW, Stewart WK, Parratt D Dextran antibodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialyzed patients. Nephrol Dial Transplant 1992, 7(1):35-39.
153. Novey HS, Pahl M, Haydik I, Vaziri ND Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy 1994, 72(3):224-228.
154. Hamstra RD, Block MH, Schocket AL Intravenous iron dextran in clinical medicine. JAMA 1980, 243(17):1726-1731.
155. Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996, 28:529-534.
156. Ferrlecit Product Insert, Watson Pharmaceuticals, Morrisstown, NJ.
157. Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 1998, 79:299-305.
158. Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 2002, 61:1830-1839.
159. Package insert: Venofer TM iron sucrose injection, American Regent Labs, Shirley, New Hampshire.
160. Charytan C, Levin N, Al-Saloum M, et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001, 37(2):300-307.
161. Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000, 36(1):88-97.
162. Silverberg DS, Blum M, Peer G, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996, 72(3):413-417.
163. Kosch M, Bahner U, Bettger H, et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs. iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEPO. Nephrol Dial Transplant 2001, 16(6):1239-1244.
164. Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002, 13(3):734-744.
165. Ajioka RS, Kushner JP Clinical consequences of iron overload in hemochromatosis homozygotes. Blood 2003, 101(9):3351-3353.
166. Gokal R, Millard PR, Weatherall DJ, et al. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload. Q J Med 1979, 48(191):369-391.
167. Ali M, Fayemi AO, Rigolosi R, et al. Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA 1980, 244(4):343-345.
168. Van de Vyver FL, Visser WJ, D'Haese PC, De Broe ME Iron overload and bone disease in chronic dialysis patients. Nephrol Dial Transplant 1990, 5(9):781-787.
169. Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981, 304(6):319-324.
170. Bregman H, Gelfand MC, Winchester JF, et al. Iron-overload-associated myopathy in patients on maintenance haemodialysis: A histocompatibility-linked disorder. Lancet 1980, 2(8200):882-885.
171. Bullen JJ Iron and infection. Eur J Clin Microbiol 1985, 4(6):537-539.
172. Rogers HJ, Bullen JJ, Cushnie GH Iron compounds and resistance to infection. Further experiments with Clostridium welchii type A in vivo and in vitro. Immunology 1970, 19(4):521-538.
173. Bullen JJ, Ward CG, Wallis SN Virulence and the role of iron in pseudomonas aeruginosa infection. Infect Immun 1974, 10(3):443-450.
174. Jones RL, Peterson CM, Grady RW, et al. Effects of iron chelators and iron overload on salmonella infection. Nature 1977, 267(5607):63-65.
175. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998, 9(4):655-663.
176. Deicher R, Ziai F, Cohen G, et al. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003, 64(2):728-736.
177. Sengoelge G, Kletzmayr J, Ferrara I, et al. Impairment of transcendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 2003, 14(10):2639-2644.
178. Kessler M, Hoen B, Mayeux D, et al. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993, 64:95-100.
179. Hoen B, Kessler M, Hestin D, Mayeux D Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 1995, 10:377-381.
180. Tielemans CL, Lenclud CM, Wens R, et al. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 1989, 4:883-887.
181. Rogers JT, Bridges KR, Durmowicz GP, et al. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 1990, 265(24):14572-14578.
182. Hoen B, Paul-Dauphin A, Hestin D, Kessler M EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998, 9:869-876.
183. Jean G, Charra B, Chazot C, et al. Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias. Nephron 2002, 91:399-405.
184. Canziani ME, Yumiya ST, Rangel EB, et al. Risk of bacterial infection in patients under intravenous iron therapy: Dose versus length of treatment. Artif Organs 2001, 25(11):866-869.
185. Hoen B, Paul-Dauphin A, Kessler M Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002, 57:457-461.
186. Parkkinen J, von Bonsdorff L, Peltonen S, et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000, 15(11):1827-1834.
187. Aisen P Transferrin, the transferrin receptor, and the uptake of iron by cells. Met Ions Biol Syst 1998, 35:585-631.
188. Griffiths WJ, Kelly AL, Cox TM Inherited disorders of iron storage and transport. Mol Med Today 1999, 5(10):431-438.
189. Seligman PA, Schleicher RB Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 1999, 45(6 Pt 1):898-901.
190. Kooistra MP, Kersting S, Gosriwatana I, et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002, 32(suppl 1):36-41.
191. Rooyakkers TM, Stroes ES, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002, 32(suppl 1):9-16.
192. Roob JM, Khoschsorur G, Tiran A, et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000, 11(3):539-549.
193. Tovbin D, Mazor D, Vorobiov M, et al. Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J
194. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002, 106(17):2212-2217.
195. Michelis R, Gery R, Sela S, et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003, 18(5):924-930.
196. Albertini R, Moratti R, De Luca G Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies. Curr Mol Med 2002, 2(6):579-592.
197. Sullivan JL Iron and the sex difference in heart disease risk. Lancet 1981, 1:1293-1294.
198. Parfrey PS, Foley RN The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999, 10:1606-1615.
199. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation 1992, 86:803-811.
200. Magnusson MK, Sigfusson N, Sigvaldason H, et al. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 1994, 89:102-108.
201. Salonen JT, Nyyssonen K, Salonen R Body iron stores and the risk of coronary heart disease. N Engl J Med 1994, 331:1159.
202. Klipstein-Grobusch K, Koster JF, Grobbee DE, et al. Serum ferritin and risk of myocardial infarction in the elderly: The Rotterdam study. Am J Clin Nutr 1999, 69:1231-1236.
203. Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998, 97:1461-1466.
204. Marniemi J, Jarvisalo J, Toikka T, et al. Blood vitamins, mineral elements and inflammation markers as risk factors of vascular and non-vascular disease mortality in an elderly population. Int J Epidemiol 1998, 27:799-807.
205. Kiechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study. Circulation 1997, 96:3300-3307.
206. Aronow WS, Ahn C Three-year follow-up shows no association of serum ferritin levels with incidence of new coronary events in 577 persons aged > or = 62 years. Am J Cardiol 1996, 78:678-679.
207. Manttari M, Manninen V, Huttunen JK, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J 1994, 15:1599-1603.
208. Frey GH, Krider DW Serum ferritin and myocardial infarct. W V Med J 1994, 90:13-15.
209. Miller M, Hutchins GM Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 1994, 272(3):231-233.